Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 16INDUSTRY 7NIH 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 22Prostatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 14Lymphoma 12Colorectal Neoplasms 12Neoplasms 9Melanoma 9Lung Neoplasms 8Leukemia, Myeloid, Acute 8Pancreatic Neoplasms 7Lymphoma, Non-Hodgkin 7Wilms Tumor 6Leukemia, Biphenotypic, Acute 6HIV Infections 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Lymphoma, Mantle-Cell 5Hematologic Neoplasms 5Head and Neck Neoplasms 5Ependymoma 5Colonic Neoplasms 5Rectal Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Medulloblastoma 4Malignant Solid Neoplasm 4

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Smoldering Multiple Myeloma × 90 days × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡